source
- Amgen reports positive Phase 3 results for Sjögren's drug; Novartis announces $900M radioligand partnershipAmgen said its CD40 ligand antagonist dazodalibep met the primary endpoint in a Phase 3 trial for Sjögren's syndrome, marking a notable achievement for the company. Novartis disclosed a $900 milli…
- GSK pursues China-centric growth after successful Hansoh licensing deals show promiseGSK says it is following a "balance West and East" strategy, increasingly looking to China for drug licensing opportunities. In 2023 the company paid a combined $270 million upfront to Hansoh Phar…